Literature DB >> 1722791

The pathophysiology of benign prostatic hyperplasia.

J D McConnell1.   

Abstract

Although benign prostatic hyperplasia (BPH) is one of the most common disease processes affecting the aging male, surprisingly little is known about its pathophysiology. Cause-and-effect relationships have not been established, despite intense research efforts in the last four or five decades aimed at elucidating the underlying etiology of prostatic growth in older men. Previously held notions that the clinical symptoms of BPH (prostatism) are due simply to a mass-related increase in urethral resistance are too simplistic. It is now clear that a significant portion of the symptoms are due to obstruction-induced detrusor dysfunction. Moreover, obstruction may induce a variety of neural alterations in the bladder and prostate that contribute to symptomatology. Undoubtedly, the constellation of cellular pathologies that give rise to the symptoms of BPH will be far more complex than we currently realize. Only by unraveling these complexities, however, will we be able successfully to design alternative strategies to treat, and possibly prevent BPH.

Entities:  

Mesh:

Year:  1991        PMID: 1722791

Source DB:  PubMed          Journal:  J Androl        ISSN: 0196-3635


  15 in total

Review 1.  Risks versus benefits of testosterone therapy in elderly men.

Authors:  S Basaria; A S Dobs
Journal:  Drugs Aging       Date:  1999-08       Impact factor: 3.923

2.  Benign prostatic hyperplasia: an overview.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2005

3.  Bawu decoction () ameliorates benign prostatic hyperplasia in rats.

Authors:  Ji-Hwan Eom; Se-Yun Cheon; Kyung-Sook Chung; Myung-Dong Kim; Hyo-Jin An
Journal:  Chin J Integr Med       Date:  2016-11-12       Impact factor: 1.978

Review 4.  Role of prostate stem cells and treatment strategies in benign prostate hyperplasia.

Authors:  Kalyan J Gangavarapu; Peter F Jowdy; Barbara A Foster; Wendy J Huss
Journal:  Am J Clin Exp Urol       Date:  2022-06-15

5.  Inhibitory effects of Hydrocotyle ramiflora on testosterone-induced benign prostatic hyperplasia in rats.

Authors:  Suyoung Park; Youn-Hwan Hwang; Eun-Bok Baek; Eun-Ju Hong; Young-Suk Won; Hyo-Jung Kwun
Journal:  Int Urol Nephrol       Date:  2022-09-15       Impact factor: 2.266

6.  Prostate histotripsy in an anticoagulated model.

Authors:  Jeffery C Wheat; Timothy L Hall; Christopher R Hempel; Charles A Cain; Zhen Xu; William W Roberts
Journal:  Urology       Date:  2009-11-22       Impact factor: 2.649

Review 7.  The long-term cost effectiveness of treatments for benign prostatic hyperplasia.

Authors:  Rachael L DiSantostefano; Andrea K Biddle; John P Lavelle
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

Review 8.  Management of Benign Prostatic Hyperplasia Larger than 100 ml: Simple Open Enucleation Versus Transurethral Laser Prostatectomy.

Authors:  Mohamed A Elkoushy; Mostafa M Elhilali
Journal:  Curr Urol Rep       Date:  2016-06       Impact factor: 3.092

9.  Effects of electroacupuncture on benign prostate hyperplasia patients with lower urinary tract symptoms: a single-blinded, randomized controlled trial.

Authors:  Jung-Sheng Yu; Kun-Hung Shen; Wen-Chi Chen; Jiann-Shyan Her; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2011-04-13       Impact factor: 2.629

10.  Effect of 5-alpha Reductase Inhibitor on Storage Symptoms in Patients with Benign Prostatic Hyperplasia.

Authors:  Kang Jun Cho; Se Hee Kang; Hyo Sin Kim; Jun Sung Koh; Joon Chul Kim
Journal:  Int Neurourol J       Date:  2011-09-30       Impact factor: 2.835

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.